Log in
NYSE:BSX

Boston Scientific Competitors

$33.33
-0.37 (-1.10 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$32.99
Now: $33.33
$33.91
50-Day Range
$33.50
MA: $37.15
$41.97
52-Week Range
$24.10
Now: $33.33
$46.62
Volume18.20 million shs
Average Volume10.72 million shs
Market Capitalization$47.73 billion
P/E Ratio12.77
Dividend YieldN/A
Beta0.98

Competitors

Boston Scientific (NYSE:BSX) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying BSX stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Boston Scientific, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Risk & Volatility

Abbott Laboratories has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Abbott Laboratories and Boston Scientific, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
Boston Scientific031833.00

Abbott Laboratories presently has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Boston Scientific has a consensus target price of $43.80, suggesting a potential upside of 31.41%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Boston Scientific36.59%11.54%5.55%

Earnings and Valuation

This table compares Abbott Laboratories and Boston Scientific's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73
Boston Scientific$10.74 billion4.45$4.70 billion$1.5821.09

Boston Scientific has lower revenue, but higher earnings than Abbott Laboratories. Boston Scientific is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 82.7% of Boston Scientific shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 0.7% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Boston Scientific beats Abbott Laboratories on 8 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Risk & Volatility

Boston Scientific has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Boston Scientific and Medtronic, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific031833.00
Medtronic132012.84

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Medtronic has a consensus target price of $118.1538, indicating a potential upside of 6.47%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Medtronic.

Profitability

This table compares Boston Scientific and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific36.59%11.54%5.55%
Medtronic15.80%10.47%5.80%

Earnings & Valuation

This table compares Boston Scientific and Medtronic's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$10.74 billion4.45$4.70 billion$1.5821.09
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18

Medtronic has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 79.9% of Medtronic shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 0.5% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Boston Scientific beats Medtronic on 8 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Risk & Volatility

Boston Scientific has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Boston Scientific and Stryker, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific031833.00
Stryker291512.56

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Stryker has a consensus target price of $221.44, indicating a potential downside of 4.97%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Stryker.

Profitability

This table compares Boston Scientific and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific36.59%11.54%5.55%
Stryker11.38%20.53%8.89%

Earnings & Valuation

This table compares Boston Scientific and Stryker's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$10.74 billion4.45$4.70 billion$1.5821.09
Stryker$14.88 billion5.88$2.08 billion$8.2628.21

Boston Scientific has higher earnings, but lower revenue than Stryker. Boston Scientific is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 71.0% of Stryker shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 6.8% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Boston Scientific beats Stryker on 8 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Risk & Volatility

Boston Scientific has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Institutional and Insider Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Boston Scientific and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific36.59%11.54%5.55%
Intuitive Surgical24.45%12.08%10.44%

Analyst Recommendations

This is a summary of current recommendations and price targets for Boston Scientific and Intuitive Surgical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific031833.00
Intuitive Surgical371202.41

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Intuitive Surgical has a consensus target price of $718.2778, indicating a potential downside of 0.11%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Intuitive Surgical.

Earnings & Valuation

This table compares Boston Scientific and Intuitive Surgical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$10.74 billion4.45$4.70 billion$1.5821.09
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27

Boston Scientific has higher revenue and earnings than Intuitive Surgical. Boston Scientific is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

Boston Scientific has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Insider & Institutional Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Boston Scientific and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific36.59%11.54%5.55%
Becton, Dickinson and5.11%13.30%5.60%

Analyst Ratings

This is a breakdown of current ratings and price targets for Boston Scientific and Becton, Dickinson and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific031833.00
Becton, Dickinson and07712.60

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Becton, Dickinson and has a consensus target price of $280.2857, indicating a potential upside of 22.67%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities analysts clearly believe Boston Scientific is more favorable than Becton, Dickinson and.

Earnings and Valuation

This table compares Boston Scientific and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$10.74 billion4.45$4.70 billion$1.5821.09
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Boston Scientific has higher earnings, but lower revenue than Becton, Dickinson and. Boston Scientific is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats Becton, Dickinson and on 10 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

Boston Scientific has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Boston Scientific and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Scientific36.59%11.54%5.55%
Edwards Lifesciences18.18%29.00%18.10%

Analyst Ratings

This is a breakdown of current ratings and price targets for Boston Scientific and Edwards Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Scientific031833.00
Edwards Lifesciences251302.55

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Edwards Lifesciences has a consensus target price of $87.7222, indicating a potential upside of 3.57%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities analysts clearly believe Boston Scientific is more favorable than Edwards Lifesciences.

Earnings and Valuation

This table compares Boston Scientific and Edwards Lifesciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$10.74 billion4.45$4.70 billion$1.5821.09
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54

Boston Scientific has higher revenue and earnings than Edwards Lifesciences. Boston Scientific is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats Edwards Lifesciences on 9 of the 15 factors compared between the two stocks.


Boston Scientific Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27-1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97-0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01-0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05-1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48-1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70-0.2%$52.79 billion$4.35 billion67.76
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79-1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77-1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09-1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57-0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89-0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07-1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14-0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09-3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50-0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50-1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43-0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55-0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47-1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78-0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98-0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32-2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18-2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37-2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24-1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90-1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55-2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87-4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14-2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12-2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52-0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40-11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98-1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94-1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.